Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain

References

• Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer’s dementia. Drug Discov Today 1996, 1, 53–59.
   Web of Science ®Google Scholar
• Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer’s disease. Eur J Pharmacol 2000, 393, 165–170.
   PubMed Web of Science ®Google Scholar
• Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lübbert H, Albuquerque EX, Maelicke A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003, 305, 1024–1036.
   PubMed Web of Science ®Google Scholar
• Texidó L, Ros E, Martín-Satué M, López S, Aleu J, Marsal J, Solsona C. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity. Br J Pharmacol 2005, 145, 672–678.
   PubMed Web of Science ®Google Scholar
• Thomsen T, Kaden B, Fischer JP, Bickel U, Barz H, Gusztony G, Cervos-Navarro J, Kewitz H. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991, 29, 487–492.
   PubMedGoogle Scholar
• Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, Sachak S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 2005, 1033, 186–193.
   PubMed Web of Science ®Google Scholar
• Alkondon M, Braga MF, Pereira EF, Maelicke A, Albuquerque EX. alpha7 nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus. Eur J Pharmacol 2000, 393, 59–67.
   PubMed Web of Science ®Google Scholar
• Woodruff-Pak DS, Vogel RW 3rd, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA 2001, 98, 2089–2094.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou FM, Dani JA. Cholinergic drugs for Alzheimer’s disease enhance in vitro dopamine release. Mol Pharmacol 2004, 66, 538–544.
   PubMed Web of Science ®Google Scholar
• Hurst RS, Hajós M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, Groppi VE, Allaman G, Ogier R, Bertrand S, Bertrand D, Arneric SP. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 2005, 25, 4396–4405.
   PubMed Web of Science ®Google Scholar
• Maelicke A. In:Ritchie CW, Ames D, Masters CL, Cummings J, eds. Therapeutic Strategies in Dementia. Oxford: Clinical Publishing, 2007, 153–172.
   Google Scholar
• Albuquerque EX, Pereira EF, Aracava Y, Fawcett WP, Oliveira M, Randall WR, Hamilton TA, Kan RK, Romano JA Jr, Adler M. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc Natl Acad Sci USA 2006, 103, 13220–13225.
   PubMed Web of Science ®Google Scholar
• Storch A, Schrattenholz A, Cooper JC, Abdel Ghani EM, Gutbrod O, Weber KH, Reinhardt S, Lobron C, Hermsen B, Soskiç V. Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells. Eur J Pharmacol 1995, 290, 207–219.
   PubMed Web of Science ®Google Scholar
• Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996, 49, 1–6.
   PubMed Web of Science ®Google Scholar
• Kuhlmann J, Okonjo KO, Maelicke A. Desensitization is a property of the cholinergic binding region of the nicotinic acetylcholine receptor, not of the receptor-integral ion channel. FEBS Lett 1991, 279, 216–218.
   PubMed Web of Science ®Google Scholar
• Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. Mechanism of action of galantamine on N-methyl-d-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 2004, 310, 933–942.
   PubMed Web of Science ®Google Scholar
• Faghih R, Gfesser GA, Gopalakrishnan M. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor. Recent Pat CNS Drug Discov 2007, 2, 99–106.
   PubMedGoogle Scholar
• Caterina J. ‘Patentwatch’. Nat Rev Drug Discovery, 2009, 8, 691.
   Google Scholar
• Bertrand D, Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 2007, 74, 1155–1163.
   PubMed Web of Science ®Google Scholar
• Young GT, Zwart R, Walker AS, Sher E, Millar NS. Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 2008, 105, 14686–14691.
   PubMed Web of Science ®Google Scholar
• Schröder B, Reinhardt-Maelicke S, Schrattenholz A, McLane KE, Kretschmer A, Conti-Tronconi BM, Maelicke A. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide. J Biol Chem 1994, 269, 10407–10416.
   PubMed Web of Science ®Google Scholar
• Schrattenholz A, Godovac-Zimmermann J, Schäfer HJ, Albuquerque EX, Maelicke A. Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine. Eur J Biochem 1993, 216, 671–677.
   PubMedGoogle Scholar
• Akk G, Steinbach JH. Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site. J Neurosci 2005, 25, 1992–2001.
   PubMed Web of Science ®Google Scholar
• Le Novère N, Grutter T, Changeux JP. Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2+-binding sites. Proc Natl Acad Sci USA 2002, 99, 3210–3215.
   PubMed Web of Science ®Google Scholar
• Costa V, Nistri A, Cavalli A, Carloni P. A structural model of agonist binding to the alpha3beta4 neuronal nicotinic receptor. Br J Pharmacol 2003, 140, 921–931.
   PubMed Web of Science ®Google Scholar
• Celie PH, Klaassen RV, van Rossum-Fikkert SE, van Elk R, van Nierop P, Smit AB, Sixma TK. Crystal structure of acetylcholine-binding protein from Bulinus truncatus reveals the conserved structural scaffold and sites of variation in nicotinic acetylcholine receptors. J Biol Chem 2005, 280, 26457–26466.
   PubMed Web of Science ®Google Scholar
• Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 2005, 346, 967–989.
   PubMed Web of Science ®Google Scholar
• Iorga B, Herlem D, Barré E, Guillou C. Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the ‘blind docking’ approach. J Mol Model 2006, 12, 366–372.
   PubMed Web of Science ®Google Scholar
• Luttmann E, Ludwig J, Höffle-Maas A, Samochocki M, Maelicke A, Fels G. Structural model for the binding sites of allosterically potentiating ligands on nicotinic acetylcholine receptors. ChemMedChem 2009, 4, 1874–1882.
   PubMed Web of Science ®Google Scholar
• Hansen SB, Taylor P. Galanthamine and noncompetitive inhibitor binding to ACh-binding protein: evidence for a binding site on nonalpha-subunit interfaces of heteromeric neuronal nicotinic receptors. J Mol Biol 2007, 369, 895–901.
   PubMed Web of Science ®Google Scholar
• Eiselé JL, Bertrand S, Galzi JL, Devillers-Thiéry A, Changeux JP, Bertrand D. Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 1993, 366, 479–483.
   PubMed Web of Science ®Google Scholar
• Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001, 411, 269–276.
   PubMed Web of Science ®Google Scholar
• Henchman RH, Wang HL, Sine SM, Taylor P, McCammon JA. Ligand-induced conformational change in the alpha7 nicotinic receptor ligand binding domain. Biophys J 2005, 88, 2564–2576.
   PubMed Web of Science ®Google Scholar
• Smart L, Meyers HW, Hilgenfeld R, Saenger W, Maelicke A. A structural model for the ligand-binding sites at the nicotinic acetylcholine receptor. FEBS Lett, 1994, 178, 64–68.
   Google Scholar
• Galzi JL, Revah F, Black D, Goeldner M, Hirth C, Changeux JP. Identification of a novel amino acid alpha-tyrosine 93 within the cholinergic ligands-binding sites of the acetylcholine receptor by photoaffinity labeling. Additional evidence for a three-loop model of the cholinergic ligands-binding sites. J Biol Chem 1990, 265, 10430–10437.
   PubMed Web of Science ®Google Scholar
• Ohno K, Wang HL, Milone M, Bren N, Brengman JM, Nakano S, Quiram P, Pruitt JN, Sine SM, Engel AG. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit. Neuron 1996, 17, 157–170.
   PubMed Web of Science ®Google Scholar
• Pereira EF, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, Albuquerque EX. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther 1993, 265, 1474–1491.
   PubMed Web of Science ®Google Scholar
• Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand, Suppl 2000, 176, 68–73.
   PubMedGoogle Scholar
• Covarrubias M, Prinz H, Meyers HW, Maelicke A. Equilibrium binding of cholinergic ligands to the membrane-bound acetylcholine receptor. J Biol Chem 1986, 261, 14955–14964.
   PubMed Web of Science ®Google Scholar
• Maelicke A, Schröder B, Reinhardt-Maelicke S, McLane K, Diethelm BM, Conti-Tronconi BM. Nicotinic acetylcholine receptors have ligand-specific attachment point patterns. J Recept Res 1991, 11, 425–435.
   PubMed Web of Science ®Google Scholar
• Okonjo KO, Kuhlmann J, Maelicke A. A second pathway of activation of the Torpedo acetylcholine receptor-channel. Eur J Biochem 1991, 200, 671–677.
   PubMedGoogle Scholar
• Peter C, Korngreen A, Witzemann V. Mutation of single murine acetylcholine receptor subunits reveals differential contribution of P121 to acetylcholine binding and channel opening. Pflugers Arch 2005, 450, 178–184.
   PubMed Web of Science ®Google Scholar
• Criado M, Mulet J, Bernal JA, Gerber S, Sala S, Sala F. Mutations of a conserved lysine residue in the N-terminal domain of alpha7 nicotinic receptors affect gating and binding of nicotinic agonists. Mol Pharmacol 2005, 68, 1669–1677.
   PubMed Web of Science ®Google Scholar
• Bernal JA, Mulet J, Castillo M, Criado M, Sala F, Sala S. Single-channel study of the binding-gating coupling in the slowly desensitizing chimeric alpha7-5HT3A receptor. FEBS Lett 2009, 583, 1045–1051.
   PubMed Web of Science ®Google Scholar
• Mukhtasimova N, Free C, Sine SM. Initial coupling of binding to gating mediated by conserved residues in the muscle nicotinic receptor. J Gen Physiol 2005, 126, 23–39.
   PubMed Web of Science ®Google Scholar
• Monod J, Wyman J, Changeux JP. On the nature of allosteric transitions: a plausible model. J Mol Biol 1965, 12, 88–118.
   PubMed Web of Science ®Google Scholar
• Changeux JP, Thiéry J, Tung Y, Kittel C. On the cooperativity of biological membranes. Proc Natl Acad Sci USA 1967, 57, 335–341.
   PubMed Web of Science ®Google Scholar
• Langley JN. On nerve endings and on special excitable substances in cells. Croonian Lecture. Proceedings of the Royal Society of London, 1906, B 78, 170–194.
   Google Scholar
• Prinz H, Maelicke A. Interaction of cholinergic ligands with the purified acetylcholine receptor protein. I. Equilibrium binding studies. J Biol Chem 1983, 258, 10263–10271.
   PubMed Web of Science ®Google Scholar
• Prinz H, Maelicke A. Ligand binding to the membrane-bound acetylcholine receptor from Torpedo marmorata: a complete mathematical analysis. Biochemistry 1992, 31, 6728–6738.
   PubMed Web of Science ®Google Scholar
• Changeux JP, Edelstein SJ. Allosteric receptors after 30 years. Neuron 1998, 21, 959–980.
   PubMedGoogle Scholar
• Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 2002, 61, 1222–1234.
   PubMed Web of Science ®Google Scholar
• Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997, 280, 1117–1136.
   PubMed Web of Science ®Google Scholar
• Kawai H, Carlson BJ, Okita DK, Raftery MA. Eserine and other tertiary amine interactions with Torpedo acetylcholine receptor postsynaptic membrane vesicles. Biochemistry 1999, 38, 134–141.
   PubMed Web of Science ®Google Scholar
• Zwart R, Vijverberg HP. Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and noncompetitive effects. Mol Pharmacol 1997, 52, 886–895.
   PubMed Web of Science ®Google Scholar
• Zwart R, van Kleef RG, Gotti C, Smulders CJ, Vijverberg HP. Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs. J Neurochem 2000, 75, 2492–2500.
   PubMed Web of Science ®Google Scholar
• Law RJ, Henchman RH, McCammon JA. A gating mechanism proposed from a simulation of a human alpha7 nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 2005, 102, 6813–6818.
   PubMed Web of Science ®Google Scholar
• Jozwiak K, Ravichandran S, Collins JR, Wainer IW. Interaction of noncompetitive inhibitors with an immobilized alpha3beta4 nicotinic acetylcholine receptor investigated by affinity chromatography, quantitative-structure activity relationship analysis, and molecular docking. J Med Chem 2004, 47, 4008–4021.
   PubMed Web of Science ®Google Scholar
• Maelicke A, Coban T, Storch A, Schrattenholz A, Pereira EF, Albuquerque EX. Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists. J Recept Signal Transduct Res 1997, 17, 11–28.
   PubMed Web of Science ®Google Scholar
• Miwa JM, Ibanez-Tallon I, Crabtree GW, Sánchez R, Sali A, Role LW, Heintz N. lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron 1999, 23, 105–114.
   PubMed Web of Science ®Google Scholar
• Miller G. Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer’s drug. Science 2010, 327, 1309.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73, 2061–2070.
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302, 2557–2564.
   PubMed Web of Science ®Google Scholar
• Bencherif M, Lippiello PM. Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer’s etiopathology? Med Hypotheses 2010, 74, 281–285.
   PubMed Web of Science ®Google Scholar
• Brumwell CL, Johnson JL, Jacob MH. Extrasynaptic alpha 7-nicotinic acetylcholine receptor expression in developing neurons is regulated by inputs, targets, and activity. J Neurosci 2002, 22, 8101–8109.
   PubMed Web of Science ®Google Scholar
• Sharma G, Vijayaraghavan S. Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. Curr Med Chem, 2008, 15, 2921–2932.
   PubMed Web of Science ®Google Scholar
• Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, Shimohama S. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 2004, 325, 976–982.
   PubMed Web of Science ®Google Scholar
• Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AK. Memogain is a galantamine prodrug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci 2010, 40, 135–137.
   PubMed Web of Science ®Google Scholar